![Dr. David Palma (@drdavidpalma) 's Twitter Profile](https://pbs.twimg.com/profile_images/1480708516272906244/MZLO69X0_200x200.jpg)
Dr. David Palma
@drdavidpalma
Radiation Oncologist & Professor, Western University | Author of Taking Charge of Cancer | Triathlete & marathon runner | Husband & dad of 3
ID: 1479910242666356740
08-01-2022 20:18:01
399 Tweet
3,3K Followers
182 Following
![Shankar Siva (@_shankarsiva) 's Twitter Profile Photo Shankar Siva (@_shankarsiva) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1177357858255470593/avWaWpzG_200x200.jpg)
NRG Oncology LU-002 #ASCOO24. Oligomet/oligoinduced #lungcancer RCT phase II, SoC +/- local consolidation #radiotherapy. NEGATIVE trial; n=215, 2-yr PFS = 36% in SoC systemic therapy arm 40% in LCT arm (HR 0.93). Puneeth Iyengar argues for biomarker selection. What next #radonc 🧐?
![Shankar Siva (@_shankarsiva) on Twitter photo <a href="/NRGonc/">NRG Oncology</a> LU-002 #ASCOO24. Oligomet/oligoinduced #lungcancer RCT phase II, SoC +/- local consolidation #radiotherapy. NEGATIVE trial; n=215, 2-yr PFS = 36% in SoC systemic therapy arm 40% in LCT arm (HR 0.93). <a href="/IyengarPuneeth/">Puneeth Iyengar</a> argues for biomarker selection. What next #radonc 🧐? <a href="/NRGonc/">NRG Oncology</a> LU-002 #ASCOO24. Oligomet/oligoinduced #lungcancer RCT phase II, SoC +/- local consolidation #radiotherapy. NEGATIVE trial; n=215, 2-yr PFS = 36% in SoC systemic therapy arm 40% in LCT arm (HR 0.93). <a href="/IyengarPuneeth/">Puneeth Iyengar</a> argues for biomarker selection. What next #radonc 🧐?](https://pbs.twimg.com/media/GO8HDSfW8AEBcKb.jpg)
![Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1480708516272906244/MZLO69X0_200x200.jpg)
A landmark trial. Why was it negative? Hard to say for sure. Maybe there is no effect of SABR in oligometastatic NSCLC, but maybe it was the relatively low SABR doses, or the patient population (mostly synchronous oligomets?) Eagerly awaiting SARON RCT results from Fiona McDonald!
![Fiona McDonald (@fifimcdrmh) 's Twitter Profile Photo Fiona McDonald (@fifimcdrmh) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/728948491918184449/Pq0uZ6t5_200x200.jpg)
Hopefully SARON results in 2025. Congratulations to Puneeth Iyengar & LU002 trial team for completing this important trial!
![Shankar Siva (@_shankarsiva) 's Twitter Profile Photo Shankar Siva (@_shankarsiva) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1177357858255470593/avWaWpzG_200x200.jpg)
Dr. David Palma Fiona McDonald Also included induced oligometastases in this study + primary was only treated in <1/3rd. Not all patients had TOTAL METASTATIC ABLATION! Caveat; retrospective data, but treatment of all sites of disease in ‘oligo’ setting we found to be important …. sciencedirect.com/science/articl…
![Shankar Siva (@_shankarsiva) on Twitter photo <a href="/drdavidpalma/">Dr. David Palma</a> <a href="/fifimcdrmh/">Fiona McDonald</a> Also included induced oligometastases in this study + primary was only treated in <1/3rd. Not all patients had TOTAL METASTATIC ABLATION! Caveat; retrospective data, but treatment of all sites of disease in ‘oligo’ setting we found to be important …. sciencedirect.com/science/articl… <a href="/drdavidpalma/">Dr. David Palma</a> <a href="/fifimcdrmh/">Fiona McDonald</a> Also included induced oligometastases in this study + primary was only treated in <1/3rd. Not all patients had TOTAL METASTATIC ABLATION! Caveat; retrospective data, but treatment of all sites of disease in ‘oligo’ setting we found to be important …. sciencedirect.com/science/articl…](https://pbs.twimg.com/media/GPFxBBmXwAAaydH.jpg)
![Dr. Denise Bernhardt (@drdbernhardt) 's Twitter Profile Photo Dr. Denise Bernhardt (@drdbernhardt) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1708833640048889856/Tbn0jijU_200x200.jpg)
🧠🗣️Trial Update Deutsche Gesellschaft für Radioonkologie e.V. 2024: Thanks to patients and trial staff Radiation Oncology @Heidelberg University Hosp. for participating in the ENCEPHALON Trial 🙏. Findings for SCLC patients: Neurocognitive decline: WBRT: 24% vs. SRS alone: 7% New: 12-month OS (secondary EP!) shows no difference. #srs #sclc
![Dr. Denise Bernhardt (@drdbernhardt) on Twitter photo 🧠🗣️Trial Update <a href="/degro_ev/">Deutsche Gesellschaft für Radioonkologie e.V.</a> 2024: Thanks to patients and trial staff <a href="/UKHD_radonc/">Radiation Oncology @Heidelberg University Hosp.</a> for participating in the ENCEPHALON Trial 🙏. Findings for SCLC patients: Neurocognitive decline: WBRT: 24% vs. SRS alone: 7% New: 12-month OS (secondary EP!) shows no difference. #srs #sclc 🧠🗣️Trial Update <a href="/degro_ev/">Deutsche Gesellschaft für Radioonkologie e.V.</a> 2024: Thanks to patients and trial staff <a href="/UKHD_radonc/">Radiation Oncology @Heidelberg University Hosp.</a> for participating in the ENCEPHALON Trial 🙏. Findings for SCLC patients: Neurocognitive decline: WBRT: 24% vs. SRS alone: 7% New: 12-month OS (secondary EP!) shows no difference. #srs #sclc](https://pbs.twimg.com/media/GQCMraTXUAAeBlF.png)
![Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1480708516272906244/MZLO69X0_200x200.jpg)
Hot off the press in IJROBP - The Red Journal: the ARREST phase I trial of SABR in poly-metastatic disease, led by Glenn Bauman, MD & Tim Nguyen Average number of lesions = 16 Dose safely escalated to 30 Gy in 5 fractions. sciencedirect.com/science/articl… The phase II/III RCT ARREST2 is underway!
![Dr. David Palma (@drdavidpalma) on Twitter photo Hot off the press in <a href="/IJROBP/">IJROBP - The Red Journal</a>: the ARREST phase I trial of SABR in poly-metastatic disease, led by <a href="/lhscradonc/">Glenn Bauman, MD</a> & <a href="/TimkWin/">Tim Nguyen</a>
Average number of lesions = 16
Dose safely escalated to 30 Gy in 5 fractions.
sciencedirect.com/science/articl…
The phase II/III RCT ARREST2 is underway! Hot off the press in <a href="/IJROBP/">IJROBP - The Red Journal</a>: the ARREST phase I trial of SABR in poly-metastatic disease, led by <a href="/lhscradonc/">Glenn Bauman, MD</a> & <a href="/TimkWin/">Tim Nguyen</a>
Average number of lesions = 16
Dose safely escalated to 30 Gy in 5 fractions.
sciencedirect.com/science/articl…
The phase II/III RCT ARREST2 is underway!](https://pbs.twimg.com/media/GSD34OrWgAALz71.png)
![Vivian Tan MD (@drviviantan) 's Twitter Profile Photo Vivian Tan MD (@drviviantan) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1625160031963324416/xkT-gJtM_200x200.jpg)
🔥Hot off the press European Urology Oncology IROCK 🇨🇦🇦🇺🇺🇸🇩🇪🇯🇵 demonstrating #SABR ⚡️yields moderate long-term renal function decline, low dialysis rates even in patients with a solitary kidney #radonc authors.elsevier.com/c/1jOzs9Cfv--d… Thankful for mentors Shankar Siva Alex Louie MD, PhD Rohann Correa
![Vivian Tan MD (@drviviantan) on Twitter photo 🔥Hot off the press <a href="/EurUrolOncol/">European Urology Oncology</a>
IROCK 🇨🇦🇦🇺🇺🇸🇩🇪🇯🇵 demonstrating #SABR ⚡️yields moderate long-term renal function decline, low dialysis rates even in patients with a solitary kidney #radonc
authors.elsevier.com/c/1jOzs9Cfv--d…
Thankful for mentors <a href="/_ShankarSiva/">Shankar Siva</a>
<a href="/DrAlexLouie/">Alex Louie MD, PhD</a> <a href="/DrCorreaRO/">Rohann Correa</a> 🔥Hot off the press <a href="/EurUrolOncol/">European Urology Oncology</a>
IROCK 🇨🇦🇦🇺🇺🇸🇩🇪🇯🇵 demonstrating #SABR ⚡️yields moderate long-term renal function decline, low dialysis rates even in patients with a solitary kidney #radonc
authors.elsevier.com/c/1jOzs9Cfv--d…
Thankful for mentors <a href="/_ShankarSiva/">Shankar Siva</a>
<a href="/DrAlexLouie/">Alex Louie MD, PhD</a> <a href="/DrCorreaRO/">Rohann Correa</a>](https://pbs.twimg.com/media/GSFHa5nWoAAdu21.jpg)
![Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1480708516272906244/MZLO69X0_200x200.jpg)
Our PGY-5 Sympascho Young MD with a few minutes of free time this afternoon, playing in our atrium for patients and staff ❤️
![Lucas C Mendez (@lucascmendez) 's Twitter Profile Photo Lucas C Mendez (@lucascmendez) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1092984723469754368/2nNrXTou_200x200.jpg)
Excellent opportunity for trainees and early staff in RadOnc and MedPhysics to sharpen their knowledge and above all their manual skills in GU and GYN brachytherapy with the stellar Western University BT team Rohann Correa Vikram Velker Joelle and others
![Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1480708516272906244/MZLO69X0_200x200.jpg)
Very proud of my good friend and med school roommate Robert Arntfield and his company Deep Breathe for winning the US Army's xTechInternational 2024 Competition! Their AI ultrasound technology will be a big step forward. London Health Sciences Centre Western University prnewswire.com/news-releases/…
![Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo Dr. David Palma (@drdavidpalma) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1480708516272906244/MZLO69X0_200x200.jpg)